Table 5 The scale for quality assessment.
Criteria | Item | Score |
|---|---|---|
Evaluation criteria | ||
WHO/RECIST | 3 | |
Not described | 0 | |
Platinum combinations | ||
One kind of platinum combinations | 3 | |
TAX/TXT, DOC, GEM, or NVB | 2 | |
Not detailed or other regimens | 1 | |
Clinical stage | ||
Detailed | 3 | |
Not detailed | 0 | |
Overall survival | ||
Original data | 3 | |
Estimation from the Kaplan–Meier curves | 1 | |
Not described | 0 | |
Median survival time | ||
Original data | 3 | |
Not described | 0 | |
Median PFS | ||
Original data | 3 | |
Estimation from the Kaplan–Meier curves | 1 | |
Not described | 0 | |
Genotyping methods | ||
3D DNA microarray | 3 | |
DNA microarray | 3 | |
DNA Sequencing | 3 | |
Illumina Golden Gate Platform | 3 | |
MALDI-TOF-MS | 3 | |
MassARRAY | 3 | |
Sequenome MS-based genotyping assay | 3 | |
SNPstream UHT | 3 | |
TaqMan | 3 | |
PCR-LDR | 2 | |
PCR-CTPP | 2 | |
PCR-CTTP | 2 | |
PCR-RFLP | 2 | |
Total sample size | ||
≥150 | 3 | |
>100 but <150 | 2 | |
≤100 | 1 | |
